Company Description
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally.
The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy.
The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn.
It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021.
Aytu Biopharma, Inc. is based in Denver, Colorado.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 150 |
| CEO | Joshua R. Disbrow |
Contact Details
Address: 7900 E. Union Avenue, Suite 920 Denver, Colorado 80237 United States | |
| Phone | (720) 437-6580 |
| Website | aytubio.com |
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754874 |
| ISIN Number | US0547548588 |
| Employer ID | 47-0883144 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chairman and Chief Executive Officer |
| Mark K. Oki CPA | Chief Financial Officer, Secretary and Treasurer |
| Greg Pyszczymuka | Chief Commercial Officer |
| Victoria Cordova | Vice President of People and Culture |
| Jarrett T. Disbrow Ph.D. | Chief Business Officer and President of Consumer Health |
| Russ McMahen | Senior Vice President of Research and Development |
| Ryan J. Selhorn CPA | Executive Vice President of Finance and Business Optimization |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | 8-K | Current Report |
| Jun 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 18, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | ARS | Filing |
| May 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 10, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |